- A
biosimilar (also
known as follow-on
biologic or
subsequent entry biologic) is a
biologic medical product that is
almost an
identical copy of an original...
-
Health Organization's List of
Essential Medicines. It is
available as a
biosimilar medication. In 2022, it was the 241st most
commonly prescribed medication...
- with the
biosimilar market valued at $8.8 billion. The
global human insulin market was
valued at $22.9
billion in 2020,
while the
biosimilar insulin market...
-
Rituximab Patent".
Center for
Biosimilars.
Retrieved 27 July 2024. "
Biosimilars of Rituximab".
Generics and
Biosimilars Initiative. 14
April 2017. Archived...
-
States in 1998, and in the
European Union in
August 1999.
Infliximab biosimilars have been
approved in the EU (2013), in ****an (2014), and in the United...
- follow-on
biosimilars will
exhibit variability in
specific variants over time. The
safety and
clinical performance of both
originator and
biosimilar biopharmaceuticals...
-
Group AG is a
Swiss company that
focuses on
generic pharmaceuticals and
biosimilars.
Prior to
October 2023, it was part of a
division of
Novartis that was...
- from
Sandoz for
Jubbonti (denosumab-bbdz), a
biosimilar to Prolia; and
Wyost (denosumab-bbdz), a
biosimilar to Xgeva. In
February 2025, the FDA approved...
- It is a
biosimilar to Eylea. In
August 2024, aflibercept-abzv (Enzeevu) was
approved for
medical use in the
United States. It is a
biosimilar to Eylea...
-
novel biologics as well as
biosimilar insulins and antibodies,
which are sold in
India as
branded formulations. Biocon's
biosimilar products are also sold...
